Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Decoding the Structural and Functional Dynamics of HER2-HER3 in Cancer through Advanced Cryo-Electron Tomography

Project description

The structural basis of human epidermal growth factor receptor signalling in cancer

Human epidermal growth factor receptor (HER) proteins are critical regulators of cell growth and have also been implicated in cancer progression. HER2 and HER3 form heterodimers that amplify tumour-promoting signals and have been linked to therapy resistance. Despite their importance, the molecular nature of the HER2-HER3 interaction within cell membranes remains elusive. With the support of the Marie Skłodowska-Curie Actions programme, the HERSTRUCT project aims to generate the 3D structure of the full-length HER2-HER3 complex using cryo-electron tomography. Researchers will investigate additional partners as well as downstream signalling events, providing fundamental insight into the role of the HER2-HER3 complex in cancer progression. Ultimately, the goal is to design novel cancer therapies for patients with HER2-driven cancers.

Objective

The HERSTRUCT project seeks to uncover the structural and functional mechanisms of HER2 and HER3, two proteins that are pivotal in driving cancer progression, particularly in aggressive breast and lung cancers. HER2 is often overexpressed in these types of cancers, leading to unchecked cell proliferation, while HER3 collaborates with HER2 to intensify the signaling pathways that sustain tumor growth and survival. Despite extensive research, the precise nature of the HER2-HER3 interaction in cancer cells, especially within their native membrane environment, remains elusive and closely linked to cancer resistance to therapies.

Leveraging cutting-edge cryo-electron tomography (cryo-ET), the HERSTRUCT project aims to produce the first 3D structural view of the full-length HER2-HER3 complex in its natural membrane environment. This approach will provide unprecedented insights into how these two proteins function together at the molecular level. Functional assays will investigate how HER2 and HER3 trigger cancer-promoting signals, while mass spectrometry will identify additional molecules interacting with the complex, offering a complete view of their role in cancer progression and therapy resistance.

In collaboration with leading research institutes, HERSTRUCT will explore how these structural insights can be applied to develop cancer therapies specifically targeting HER2-HER3 interactions. This effort not only fills a key gap in cancer research but also has the potential to lead to more personalized and effective treatments, particularly for HER2-positive cancers, where drug resistance is a challenge.

The fellowship will provide me with cutting-edge expertise in cryo-ET and advanced data analysis, strengthening my skills and preparing me for a leadership role in cancer research. This project addresses a critical challenge in cancer biology and offers the potential to improve treatment outcomes for patients with HER2-driven cancers.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2024-PF-01

See all projects funded under this call

Coordinator

MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (MDC)
Net EU contribution
€ 202 125,12
Address
ROBERT ROSSLE STRASSE 10
13125 Berlin
Germany
Region
Berlin Berlin Berlin
Activity type
Research Organisations
Links
Total cost
No data